Syngene (CMP: Rs 875; Market cap: Rs 35,216 crore; Rating: Overweight), the leading CRAMS (contract research and manufacturing services) player, posted a sequential growth in its Q2FY25 results.

Ashwin Ramaswami, a young Democrat from Johns Creek, is challenging the incumbent state senator, who was indicted alongside former President Trump for alleged interference in Georgia's 2020 election.

However, the biotech has what it takes to be successful in the challenging gene-editing niche. This company might be worth far more than many realize. If I had to buy one share of any biotech with ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Issues with supply chain sophistication: security The pharma / biotech industry’s near absence of supply-chain sophistication spans the full length of the chain, from API sourcing, through ...

US privately-held drug developer NImmune Biopharma has acquired development and commercialization rights for omilancor in Asia from Sino-American biotech LianBio. The covered markets include China, ...

Check Out Our Latest Research Report on LEGN Legend Biotech Stock Performance NASDAQ:LEGN opened at $45.04 on Monday. The company has a debt-to-equity ratio of 0.25, a current ratio of 4.84 and a ...

Case in point, her ambitious latest creation for American Ballet Theatre (ABT): an adaptation of Fyodor Dostoevsky’s 1866 novel Crime and Punishment. Alive with psychological complexity ...

Specializing in drug delivery, American biotech Zylo Therapeutics has created Z-pods, which are amorphous silica particles that have been engineered to encapsulate compounds, and can be adapted to ...

PharmAla Biotech Holdings Inc. MDXXF has announced that it will supply its Good Manufacturing Practice LaNeo MDMA for a clinical trial at Mt. Sinai Health System. The biotechnology company ...